Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ALK201
- Development stage
- Phase 2
- Lead developer
- Allink Biotherapeutics
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
ALK201 is an antibody-drug conjugate (ADC) developed by Shanghai Allink Biotherapeutics. It targets Fibroblast growth factor receptor 2b, a protein implicated in the growth of certain solid tumors. The ADC carries an undisclosed cytotoxic payload designed to selectively deliver its anti-cancer effect to tumor cells expressing Fibroblast growth factor receptor 2b. The drug is currently being evaluated in first-in-human Phase I/II clinical trials for advanced solid tumors, with ongoing studies in Australia and China. Its mechanism of action involves modulation or inhibition of Fibroblast growth factor receptor 2 signaling pathways, although the precise details remain undisclosed[1][3][4].
- Other names
- ALK 201ALK201ALK-201
02
Targets
FGFR2b (Fibroblast growth factor receptor 2 IIIb isoform)
Beyond the preview
Go deeper on ALK201.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ALK201.